A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Glioblastoma

In brief

The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.

Key facts

Study ID
NCT04485949
Run by
Imvax
People needed
99
Starts
2023-03-20
Expected to finish
2027-07-01
Last updated by the study team
2026-07-09

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.